Conatus Pharmaceuticals INC (CNAT) IPO News Nasdaq National Market.
Company Overview
Company Name : CONATUS PHARMACEUTICALS INC
Company Address : 4365 EXECUTIVE DRIVE Suite 200 San Diego, CA 92121
Company Phone : (858) 558-8130
Expected IPO Date : 7/25/2013
Company Website : www.conatuspharma.com
CEO : Steven J. Mento
Employees (as of 6/30/2013) : 15
State of Inc : DE
Fiscal Year End : 12/31
Status : Filed (6/14/2013)
Proposed Symbol : CNAT
Exchange : Nasdaq National Market
Share Price : 10.00-12.00
Shares Offered : 5,000,000
Offer Amount : $69,000,000.00
Total Expenses : $2,400,000.00
Shares Over Alloted : 750,000
Shareholder Shares Offered : --
Shares Outstanding : 14,575,485
Lockup Period (days) : 180
Lockup Expiration : --
Quiet Period Expiration : --
CIK : 0001383701
Company Description :
We are a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease. We are developing our lead compound, emricasan, for the treatment of patients in orphan populations with chronic liver disease and acute exacerbations of chronic liver disease. To date, emricasan has been studied in over 500 subjects in ten clinical trials. In a
randomized Phase 2b clinical trial in patients with liver disease, emricasan demonstrated a statistically significant, consistent, rapid and sustained reduction in elevated levels of two key biomarkers of inflammation and cell death, alanine aminotransferase, or ALT, and cleaved Cytokeratin 18, or cCK18, respectively, both of which are implicated in the severity and progression of liver disease. Our initial development strategy targets indications for emricasan with high unmet clinical need in orphan patient populations, such as patients with acute-on-chronic liver failure, or ACLF, chronic liver failure, or CLF, and patients who have developed liver fibrosis post-orthotopic liver transplant due to Hepatitis C virus infection, or HCV-POLT. We expect to initiate a Phase 2b ACLF trial and a Phase 3 HCV-POLT trial (currently designated a Phase 3 registration study in the European Union and a Phase 2b study in the United States) in the second half of 2013 and a Phase 2b CLF trial in the second half of 2014.
Emricasan is a first-in-class, orally active caspase protease inhibitor designed to reduce the activity of enzymes that mediate inflammation and cell death, or apoptosis. We believe that by reducing the activity of these enzymes, emricasan has the potential to interrupt the progression of liver disease. We have observed compelling preclinical and clinical trial results that suggest emricasan may have clinical utility in slowing progression of liver diseases regardless of the original cause of the disease. In particular, we have completed two placebo-controlled Phase 2 trials in patients with liver disease
showing statistically significant reductions in ALT levels that occur rapidly,within as little as one day after initiation of therapy, and are maintained throughout the treatment period. In our 204-patient Phase 2b trial, we also measured cCK18, an important biomarker of apoptosis and disease severity.
Statistically significant reductions in cCK18 were demonstrated in this trial as early as three hours post-dosing and were maintained for the duration of dosing.Emricasan has been generally well-tolerated in all of the clinical studies.
We were incorporated under the laws of the state of Delaware in 2005. Our principal executive offices are located at 4365 Executive Dr., Suite 200, San Diego, California 92121, and our telephone number is (858) 558-8130.
Our website address is www.conatuspharma.com.
Keyword :
Conatus Pharmaceuticals INC (CNAT) IPO News Nasdaq National Market.Conatus Pharmaceuticals INC (CNAT) IPO News Nasdaq National Market.Conatus Pharmaceuticals INC (CNAT) IPO News Nasdaq National Market.
Company Overview
Company Name : CONATUS PHARMACEUTICALS INC
Company Address : 4365 EXECUTIVE DRIVE Suite 200 San Diego, CA 92121
Company Phone : (858) 558-8130
Expected IPO Date : 7/25/2013
Company Website : www.conatuspharma.com
CEO : Steven J. Mento
Employees (as of 6/30/2013) : 15
State of Inc : DE
Fiscal Year End : 12/31
Status : Filed (6/14/2013)
Proposed Symbol : CNAT
Exchange : Nasdaq National Market
Share Price : 10.00-12.00
Shares Offered : 5,000,000
Offer Amount : $69,000,000.00
Total Expenses : $2,400,000.00
Shares Over Alloted : 750,000
Shareholder Shares Offered : --
Shares Outstanding : 14,575,485
Lockup Period (days) : 180
Lockup Expiration : --
Quiet Period Expiration : --
CIK : 0001383701
Company Description :
We are a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease. We are developing our lead compound, emricasan, for the treatment of patients in orphan populations with chronic liver disease and acute exacerbations of chronic liver disease. To date, emricasan has been studied in over 500 subjects in ten clinical trials. In a
randomized Phase 2b clinical trial in patients with liver disease, emricasan demonstrated a statistically significant, consistent, rapid and sustained reduction in elevated levels of two key biomarkers of inflammation and cell death, alanine aminotransferase, or ALT, and cleaved Cytokeratin 18, or cCK18, respectively, both of which are implicated in the severity and progression of liver disease. Our initial development strategy targets indications for emricasan with high unmet clinical need in orphan patient populations, such as patients with acute-on-chronic liver failure, or ACLF, chronic liver failure, or CLF, and patients who have developed liver fibrosis post-orthotopic liver transplant due to Hepatitis C virus infection, or HCV-POLT. We expect to initiate a Phase 2b ACLF trial and a Phase 3 HCV-POLT trial (currently designated a Phase 3 registration study in the European Union and a Phase 2b study in the United States) in the second half of 2013 and a Phase 2b CLF trial in the second half of 2014.
Emricasan is a first-in-class, orally active caspase protease inhibitor designed to reduce the activity of enzymes that mediate inflammation and cell death, or apoptosis. We believe that by reducing the activity of these enzymes, emricasan has the potential to interrupt the progression of liver disease. We have observed compelling preclinical and clinical trial results that suggest emricasan may have clinical utility in slowing progression of liver diseases regardless of the original cause of the disease. In particular, we have completed two placebo-controlled Phase 2 trials in patients with liver disease
showing statistically significant reductions in ALT levels that occur rapidly,within as little as one day after initiation of therapy, and are maintained throughout the treatment period. In our 204-patient Phase 2b trial, we also measured cCK18, an important biomarker of apoptosis and disease severity.
Statistically significant reductions in cCK18 were demonstrated in this trial as early as three hours post-dosing and were maintained for the duration of dosing.Emricasan has been generally well-tolerated in all of the clinical studies.
We were incorporated under the laws of the state of Delaware in 2005. Our principal executive offices are located at 4365 Executive Dr., Suite 200, San Diego, California 92121, and our telephone number is (858) 558-8130.
Our website address is www.conatuspharma.com.
Keyword :
Conatus Pharmaceuticals INC (CNAT) IPO News Nasdaq National Market.Conatus Pharmaceuticals INC (CNAT) IPO News Nasdaq National Market.Conatus Pharmaceuticals INC (CNAT) IPO News Nasdaq National Market.
0 comments:
Post a Comment